Item 5.07 Submission of Matters to a Vote of Security Holders.

Kinnate Biopharma Inc. (the "Company") held its Annual Meeting of Stockholders (the "Annual Meeting") on June 9, 2023. The proposals voted upon at the Annual Meeting and the voting results for each proposal are set forth below.

Proposal 1: Election of Three Class III Directors





 Name of Director      For         Withheld   Broker Non-Votes
 Nominee
 Nima Farzan           36,673,221  109,731    1,139,310

Keith Flaherty, M.D. 36,286,215 496,737 1,139,310

Dean Mitchell 33,650,999 3,131,953 1,139,310

Each director nominee was duly elected to serve until the 2026 annual meeting of stockholders and until their successor is duly elected and qualified, subject to earlier resignation or removal.

Proposal 2: Ratification of the Appointment of Independent Registered Public


             Accounting Firm



 For         Against  Abstain  Broker Non-Votes
 37,887,147  33,077   2,038    0

The stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.

--------------------------------------------------------------------------------


                      [[Image Removed: graphic]]SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

KINNATE BIOPHARMA INC.

Date: June 12, 2023 By:  /s/ Nima Farzan
                         Nima Farzan
                         Chief Executive Officer and President

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses